There is no cure for gastro esophageus, but treatment may be a step closer.

The condition is caused by the breakdown of the stomach lining and leads to a buildup of bacteria and toxins in the small intestines.

It is believed to affect around 3.3 million people in the UK and has claimed around 30,000 lives.

The new study is the first to suggest that a new type of treatment, called a type 2 diaphragm implant, could be a viable option for treating reflux.

It was carried out by researchers at Imperial College London and the University of California, San Diego.

“Our research suggests that type 2 Diaphragms are not only safe but also may be more effective than current therapies,” said Dr Simon Williams, from the UK’s Department of Health, the centre of the study.

“A number of other studies have shown they can improve the symptoms of reflux in people with reflux.”

Dr Williams, who is also from the Imperial College, said the researchers used an experimental model of the condition to demonstrate the efficacy of the treatment.

“We looked at two different models of the disease, one that involved injecting a small amount of bacteria into the small intestine and the other that involved taking a drug that inhibits bacteria in the gut.”

The results were very encouraging.

“One of the models showed significant improvement, whereas the other model showed minimal improvement.”

The researchers also used mice to demonstrate how the drug may work in humans.

They found that injections of the drug did not improve symptoms of the disorder in mice but did improve the animals’ ability to produce energy.

“These results show that a drug is not just a potential treatment but may actually be an important therapeutic tool,” Dr Williams said.

He said there was also a strong possibility that type 1 diaphrases could be able to treat reflux symptoms in people.

“Type 1 diapragms have a very low rate of failure, so the chances of success are very low.”

However, if they can be developed into a therapy, the potential is great.

“He added that if the treatment works, it could potentially reduce the number of refractory reflux episodes in people who have a low tolerance to the drug.

Dr Williams said it was a step forward in the fight against the condition.”

It is a very complex disease and one that requires treatment, but it is a relatively rare condition.

We are hopeful that we will be able do this sooner rather than later.

“The study, titled “Effect of type 2 and type 1 Diaphrasing on gastrointestinal reflux and metabolic acidosis in mice”, was published in the journal Nature Biotechnology.